Abrysvo Launch A Bright Spot For Pfizer In A Third Quarter Reset

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The RSV vaccine performed well in the third quarter but is in a competitive fight with GSK’s Arexvy. Pfizer also announced Phase III results for its mRNA-based flu vaccine.

bright spot
Pfizer's RSV vaccine got off to a strong start • Source: Shutterstock

Pfizer Inc.’s new respiratory syncytial virus (RSV) vaccine Abrysvo is off to a strong start, generating $375m in the third quarter after launching just in time for the fall season for older adults. Abrysvo was a positive development for Pfizer in a challenging quarter marked by lower sales of its two COVID-19 products – the vaccine Comirnaty and the antiviral Paxlovid.

Key Takeaways

  • Abrysvo was a positive development for Pfizer in a challenging quarter driven lower sales of COVID-19 products.

“We are really pleased with the performance of Abrysvo. It has exceeded our expectations,” chief commercial officer and biopharmaceuticals business...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.